期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 65, 期 11, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00924-21
关键词
Acinetobacter baumanii; Gram-negative resistance; novel antibiotics; nosocomial infections; durlobactam; Gram-negative bacteria; antibiotic resistance; antimicrobial agents; beta-lactamases; beta-lactams; sulbactam-durlobactam
A successful case of treating XDR Acinetobacter baumannii pneumonia and septic shock with a novel antibiotic obtained via expanded access protocol was reported, suggesting that focused research and drug development efforts can mitigate the poor outcomes associated with these infections.
Extremely drug-resistant (XDR) Acinetobacter baumannii causes challenging nosocomial infections. We report the case of a patient with XDR A. baumannii pneumonia and septic shock successfully treated with cefiderocol and a novel antibiotic obtained via expanded access protocol. With focused research and drug development efforts, the poor outcomes associated with these infections may be mitigated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据